CN106262931A - Lactobacillus plantarum application in preparation antiallergic product - Google Patents
Lactobacillus plantarum application in preparation antiallergic product Download PDFInfo
- Publication number
- CN106262931A CN106262931A CN201610633406.2A CN201610633406A CN106262931A CN 106262931 A CN106262931 A CN 106262931A CN 201610633406 A CN201610633406 A CN 201610633406A CN 106262931 A CN106262931 A CN 106262931A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- allergy
- level
- treatment
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 67
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 67
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000003266 anti-allergic effect Effects 0.000 title abstract description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 46
- 208000026935 allergic disease Diseases 0.000 claims abstract description 46
- 230000007815 allergy Effects 0.000 claims abstract description 46
- 235000013305 food Nutrition 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims description 36
- 230000028327 secretion Effects 0.000 claims description 35
- 210000004988 splenocyte Anatomy 0.000 claims description 31
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 29
- 230000036783 anaphylactic response Effects 0.000 claims description 29
- 208000003455 anaphylaxis Diseases 0.000 claims description 29
- 230000036285 pathological change Effects 0.000 claims description 29
- 231100000915 pathological change Toxicity 0.000 claims description 29
- 208000010668 atopic eczema Diseases 0.000 claims description 27
- 230000000172 allergic effect Effects 0.000 claims description 26
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 24
- 102000008192 Lactoglobulins Human genes 0.000 claims description 23
- 108010060630 Lactoglobulins Proteins 0.000 claims description 23
- 102000003814 Interleukin-10 Human genes 0.000 claims description 19
- 108090000174 Interleukin-10 Proteins 0.000 claims description 19
- 108090000978 Interleukin-4 Proteins 0.000 claims description 19
- 230000002685 pulmonary effect Effects 0.000 claims description 18
- 208000006673 asthma Diseases 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 201000009961 allergic asthma Diseases 0.000 claims description 13
- 208000037816 tissue injury Diseases 0.000 claims description 12
- 230000008817 pulmonary damage Effects 0.000 claims description 8
- 230000000774 hypoallergenic effect Effects 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 206010070834 Sensitisation Diseases 0.000 description 19
- 230000008313 sensitization Effects 0.000 description 19
- 102000004388 Interleukin-4 Human genes 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- 239000012930 cell culture fluid Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009724 venous congestion Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000007230 Sorghum bicolor Nutrition 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- -1 compound vitamin Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000004887 epithelial permeability Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000013360 fish flour Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Abstract
The invention discloses Lactobacillus plantarum application in preparation antiallergic product.The invention provides Lactobacillus plantarum in preparation for preventing and/or treating the application in the product of allergy；Described Lactobacillus plantarum is Lactobacillus plantarum (Lactobacillus plantarum) SC9, and its deposit number is CCTCC NO.M 208150.The present invention also protects a kind of product for preventing and/or treat allergy, and its active component is Lactobacillus plantarum；Described Lactobacillus plantarum is Lactobacillus plantarum (Lactobacillus plantarum) SC9, and its deposit number is CCTCC NO.M 208150.Present invention can apply to food, health product and medicine field, there is extraordinary industrial prospect.
Description
Technical field
The present invention relates to Lactobacillus plantarum application in preparation antiallergic product.
Background technology
Food anaphylaxis is the species transformation that the main allergen abnormal immunne response of generation in food is caused by body
Reaction, can cause the diseases such as allergic rhinitis, asthma, eczema, atopic dermatitis, diarrhoea, gastrointestinal hemorrhage.
In China, food anaphylaxis population sickness rate is 1%-2%, is then 8% child, and its kind and scope have increasing
The trend added.Food anaphylaxis is the disease with all one's life, has generation mortality anaphylaxis to obtain dangerous at any time.And to allergy
The feared state of mind of reaction and the negative shadow huge to the generation of patients ' psychological, nutritional development and life style to the high selectivity of food
Ring.So food anaphylaxis has been not only a simple medical problem, but become a kind of serious public health problem.
The traditional therapy of anaphylactic disease is mainly medicine control, and avoids contact with anaphylactogen the most as far as possible.
Additionally, the most also allow allergic symptom be eased in thinking with positive method.
Probiotic bacteria is the profitable strain in human body intestinal canal, can treat dyspepsia, diarrhoea etc. with regulating intestinal canal colony balance
Disease.
Summary of the invention
It is an object of the invention to provide Lactobacillus plantarum application in preparation antiallergic product.
The invention provides Lactobacillus plantarum in preparation for preventing and/or treating the application in the product of allergy；Described
Lactobacillus plantarum is Lactobacillus plantarum (Lactobacillus plantarum) SC9, and its deposit number is CCTCC NO.M
208150。
Described product is food, health product or medicine.
Described allergy is food anaphylaxis.
Described food anaphylaxis concretely Lac Bovis seu Bubali beta lactoglobulin allergy.
Ben Aming also protects Lactobacillus plantarum application in preparing product；Described Lactobacillus plantarum is Lactobacillus plantarum
(Lactobacillus plantarum) SC9, its deposit number is CCTCC NO.M 208150；
The function of described product is at least one in following (a1) to (a24):
(a1) treatment allergy；
(a2) pre-hypo-allergenic；
(a3) treatment food anaphylaxis；
(a4) prevention food anaphylaxis；
(a5) treatment Lac Bovis seu Bubali beta lactoglobulin allergy；
(a6) prevention Lac Bovis seu Bubali beta lactoglobulin allergy；
(a7) treatment allergic asthma；
(a8) prevention allergic asthma；
(a9) treatment irritable bowel syndrome pathological changes；
(a10) prevention irritable bowel syndrome pathological changes；
(a11) treatment irritable bowel syndrome tissue injury；
(a12) prevention irritable bowel syndrome tissue injury；
(a13) treatment Allergic pulmonary pathological changes；
(a14) prevention Allergic pulmonary pathological changes；
(a15) treatment Allergic pulmonary damage；
(a16) prevention Allergic pulmonary damage；
(a17) serum total IgE level is reduced；
(a18) allergy sufferers serum total IgE level is reduced；
(a19) level of splenocyte secretion IL-4 is reduced；
(a20) level of allergy sufferers splenocyte secretion IL-4 is reduced；
(a21) level of splenocyte secretion of gamma-IFN is improved；
(a22) level of allergy sufferers splenocyte secretion of gamma-IFN is improved；
(a23) level of splenocyte secretion IL-10 is improved；
(a24) level of allergy sufferers splenocyte secretion IL-10 is improved.
Described allergic asthma can be the allergic asthma that Lac Bovis seu Bubali beta lactoglobulin causes.
Described irritable bowel syndrome pathological changes can be the irritable bowel syndrome pathological changes that Lac Bovis seu Bubali beta lactoglobulin causes.
Described irritable bowel syndrome tissue injury can be the irritable bowel syndrome tissue injury that Lac Bovis seu Bubali beta lactoglobulin causes.
Described Allergic pulmonary pathological changes can be the Allergic pulmonary pathological changes that Lac Bovis seu Bubali beta lactoglobulin causes.
Described Allergic pulmonary pathological changes can be the Allergic pulmonary pathological changes that Lac Bovis seu Bubali beta lactoglobulin causes.
Described product is food, health product or medicine.
Described allergy is food anaphylaxis.
Described food anaphylaxis concretely Lac Bovis seu Bubali beta lactoglobulin allergy.
The present invention also protects a kind of product for preventing and/or treat allergy, and its active component is Lactobacillus plantarum；Institute
Stating Lactobacillus plantarum is Lactobacillus plantarum (Lactobacillus plantarum) SC9, and its deposit number is CCTCC NO.M
208150。
Described product is food, health product or medicine.
Described allergy is food anaphylaxis.
Described food anaphylaxis concretely Lac Bovis seu Bubali beta lactoglobulin allergy.
The present invention also protects a kind of product, and its active component is Lactobacillus plantarum；Described Lactobacillus plantarum is plant breast bar
Bacterium (Lactobacillus plantarum) SC9, its deposit number is CCTCC NO.M 208150；
The function of described product is at least one in following (a1) to (a24):
(a1) treatment allergy；
(a2) pre-hypo-allergenic；
(a3) treatment food anaphylaxis；
(a4) prevention food anaphylaxis；
(a5) treatment Lac Bovis seu Bubali beta lactoglobulin allergy；
(a6) prevention Lac Bovis seu Bubali beta lactoglobulin allergy；
(a7) treatment allergic asthma；
(a8) prevention allergic asthma；
(a9) treatment irritable bowel syndrome pathological changes；
(a10) prevention irritable bowel syndrome pathological changes；
(a11) treatment irritable bowel syndrome tissue injury；
(a12) prevention irritable bowel syndrome tissue injury；
(a13) treatment Allergic pulmonary pathological changes；
(a14) prevention Allergic pulmonary pathological changes；
(a15) treatment Allergic pulmonary damage；
(a16) prevention Allergic pulmonary damage；
(a17) serum total IgE level is reduced；
(a18) allergy sufferers serum total IgE level is reduced；
(a19) level of splenocyte secretion IL-4 is reduced；
(a20) level of allergy sufferers splenocyte secretion IL-4 is reduced；
(a21) level of splenocyte secretion of gamma-IFN is improved；
(a22) level of allergy sufferers splenocyte secretion of gamma-IFN is improved；
(a23) level of splenocyte secretion IL-10 is improved；
(a24) level of allergy sufferers splenocyte secretion IL-10 is improved.
Described allergic asthma can be the allergic asthma that Lac Bovis seu Bubali beta lactoglobulin causes.
Described irritable bowel syndrome pathological changes can be the irritable bowel syndrome pathological changes that Lac Bovis seu Bubali beta lactoglobulin causes.
Described irritable bowel syndrome tissue injury can be the irritable bowel syndrome tissue injury that Lac Bovis seu Bubali beta lactoglobulin causes.
Described Allergic pulmonary pathological changes can be the Allergic pulmonary pathological changes that Lac Bovis seu Bubali beta lactoglobulin causes.
Described Allergic pulmonary pathological changes can be the Allergic pulmonary pathological changes that Lac Bovis seu Bubali beta lactoglobulin causes.
Described product is food, health product or medicine.
Described allergy is food anaphylaxis.
Described food anaphylaxis concretely Lac Bovis seu Bubali beta lactoglobulin allergy.
The concretely fermentation milk of food described in any of the above, cheese, milk beverage, solid beverage etc..
The concretely functional food of food described in any of the above, such as functional yoghourt, functional microbial inoculum etc..
Medicine described in any of the above can be capsule, powder, tablets and other formulations.
Medicine described in any of the above may also include other pharmaceutically acceptable excipient or diluent.
The recommended doses of described Lactobacillus plantarum is as follows: 3 times a week, and single dose is 108～1011CFU。
In the present invention, with international allergic model animal Balb/c mice as laboratory animal, lumbar injection β-milk-globule egg
(β-lg) sets up sensitization model in vain.Treatment group and prevention group mice gavage Lactobacillus plantarum SC9 respectively, intends from internal, external two
Aspect research Lactobacillus plantarum SC9 whether can alleviate anaphylaxis and specifically mechanism.Result of study shows, gavage plant breast bar
After bacterium SC9, in sensitized mice body, IgE level significantly reduces, and Lactobacillus plantarum SC9 can lower IL-4 in sensitized mice body
Secretion level, raise IFN-γ, the secretion level of IL-10.Tissue pathological slice result shows: sensitization group mouse Colon tissue
Substantially damage occur, intestinal villus is the most damaged, and structure is unclear, and enterocyte necrosis comes off, after gavage Lactobacillus plantarum SC9,
Intestinal villus epithelium has no the most downright bad exfoliative cyte, and intestinal villus arrangement is the most neat；Sensitization group lung tissue shows blood capillary
Pipe and the phenomenon such as venous congestion, hyperemia, alveolar collapse, and after gavage Lactobacillus plantarum SC9, above-mentioned phenomenon be improved significantly.
The present invention utilizes probiotic bacteria antiallergic, the problem that when can solve to use Drug therapy anaphylaxis, side effect is big.
Additionally, the probiotic bacteria deriving from human body or fermented food is safe and effective, low price, also may be used while playing antianaphylaxis function
With regulating intestinal canal colony balance, prevent other disease of immune system.The present invention provides new direction for treatment anaphylactic disease.This
Invention can be applicable to food, health product and medicine field, has extraordinary industrial prospect.
Accompanying drawing explanation
Fig. 1 is the change of IgE level in mice serum.
Fig. 2 is the pathology section of colon.
Fig. 3 is the pathology section of lung tissue.
Detailed description of the invention
Below example facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiment
Method, if no special instructions, is conventional method.Test material used in following embodiment, if no special instructions, is certainly
Routine biochemistry reagent shop is commercially available.Quantitative test in following example, is respectively provided with three times and repeats experiment, and result is made even
Average.
6-8 week old female cleaning grade Balb/c mice: Changchun Biological Products Institute；Feeding environment: 23 ± 2 DEG C, humidity
50%-75%, freely absorbs autoclaved normal feedstuff and pure water.Normal feedstuff (without milk and milk product): Changchun
Institute of biological products；Formula (% representation quality ratio): meat powder and bone meal 5.5%, fish flour 6%, Sorghum vulgare Pers. powder 12.5%, Testa Tritici
12%, wheat flour 16%, Semen Maydis powder 30%, soybean cake 18%；Energy composition (% representation quality ratio): total protein 18%, always fat
7%, compound vitamin 0.15%, complex mineral prime element 0.35%.
Cell culture fluid completely: containing 10% (volume ratio) hyclone, 100IU/mL penicillin and 100 μ g/m L strepto-s
The RPMI-1640 cell culture fluid of element.
For detecting the test kit that the article No. that test kit is biolegend company is BL-431104 of IL-4.For detecting
The test kit of IFN-γ is the test kit that article No. is BL-430804 of biolegend company.For detecting the test kit of IL-10
The test kit that article No. is BL-431414 for biolegend company.For detecting the test kit of IgE level in mice serum it is
The IgE ELISA kit (article No. EB-88-50460-22) of ebioscience company.
If no special instructions, PBS used in embodiment is the PBS of pH7.4,0.1M.
Lac Bovis seu Bubali beta lactoglobulin (β-lg): pressed powder, purchased from Sigma-Aldrich Corporation, article No.
L3908-1G.During use, it is prepared as β-lg the solution of variable concentrations with PBS.
Freund adjuvant: liquid, purchased from Sigma-Aldrich Corporation, article No. F5881-6X10ML.
Embodiment 1, the acquisition of Lactobacillus plantarum SC9
Bacterial strain SC9, is isolatable from the Northeast's traditional zymotic sauerkraut.Physiology and biochemistry is accredited as gram positive bacteria, warp
API50CH (Mei Liai company of France) and 16srDNA sequence amplification comparison are accredited as Lactobacillus plantarum (Lactobacillus
Plantarum), named Lactobacillus plantarum (Lactobacillus plantarum) SC9, is called for short Lactobacillus plantarum SC9.
Lactobacillus plantarum SC9, is preserved in China typical culture collection center on October 10th, 2008 and (is called for short
CCTCC, address is: Wuhan University), preserving number is CCTCC NO.M 208150.
Lactobacillus plantarum SC9 applies for a patent in December in 2008 and obtains mandate on the 11st.Patent No. ZL 2,008 1
0239475.0.Authorized announcement date is on 01 04th, 2012.Authorization Notice No. is CN 101748083 B.
Embodiment 2, the antiallergic effect of Lactobacillus plantarum SC9
One, bacteria suspension and the preparation of anaphylactogen
With PBS suspension plant lactobacillus SC9, obtaining bacteria concentration is 109The bacteria suspension of CFU/mL.
1mL Freund adjuvant and 1mL 1mg/mL β-lg solution are mixed, obtains anaphylactogen.
Two, packet transaction
Experimental animal is 6-8 week old female cleaning grade Balb/c mice.
Take experimental animal, carry out adaptability for three days on end and raise (the-3rd day, the-2nd day, the-1st day), be then randomly divided into
4 groups, often group 10, process as follows:
Blank group (K): the 1st day, the 3rd day, the 5th day, the 8th day, the 10th day, the 12nd day, gavage gives a PBS and delays respectively
Rush liquid (it is 0.1mL that single gives dosage), within the 14th day, put to death experimental animal；
Sensitization group (M): the 0th day, the 7th day and the 14th day, (single gives dosage to anaphylactogen of lumbar injection respectively
0.2mL)；Third time injection anaphylactogen, after 6 hours, puts to death experimental animal；
Prevention group (Y): the 1st day, the 3rd day, the 5th day, the 8th day, the 10th day, the 12nd day, the 15th day, the 17th day and the 19th
My god, gavage gives the bacteria suspension (it is 0.1mL that single gives dosage) of step one preparation respectively；7th day, the 14th day and the 21st
My god, anaphylactogen of lumbar injection (it is 0.2mL that single gives dosage) respectively；Third time injection anaphylactogen, after 6 hours, puts to death examination
Test animal；
Treatment group (Z): the 0th day, the 7th day and the 14th day, (single gives dosage to anaphylactogen of lumbar injection respectively
0.2mL)；15th day, the 17th day, the 19th day, the 22nd day, the 24th day, the 26th day, the 29th day, the 31st day and the 33rd day, fill respectively
Stomach gives the bacteria suspension (it is 0.1mL that single gives dosage) of step one preparation；35th day, put to death experimental animal.
Three, splenocyte is secreted the impact of IL-4, IFN-γ and IL-10 by Lactobacillus plantarum SC9
Cytokine is to be divided by panimmunity cells such as monocytes/macrophages, T lymphocyte, bone-marrow-derived lymphocyte and NK cells
Secrete, be combined with the specific receptor of cell surface and cause intracellular a series of signal to present, make body produce immunne response,
Play immunoregulation effect and cause inflammatory reaction.The cells such as Th1 cell Major Secretory IFN-γ, TNF-α, Il-12 and TNF-β
The factor, suppression body produces IgE.The cytokines such as Th2 cell Major Secretory IL-4, IL-5, promote that body produces IgE.Treg
IL-10 with the Th17 cell Major Secretory IL-17 of emiocytosis mutually restricts.Mutually stimulate between cytokine, in dynamic equilibrium
The cellular immunization of middle regulation body.
1, after putting to death experimental animal, spleen, separating Morr. cell are taken.
2,6 porocyte culture plates are taken: first hole adds the naive mice splenocyte suspended with complete cell culture fluid
(cumulative volume is 5mL, and the concentration of splenocyte is 2 × 106Individual cell/mL), second hole adds with the suspension of complete cell culture fluid
Sensitization group mouse boosting cell and β-lg solution (cumulative volume is 5mL, and the concentration of splenocyte is 2 × 106Individual cell/mL, β-lg is dense
Degree for 1mg/mL), the 3rd hole adds the prevention group mouse boosting cell with the suspension of complete cell culture fluid, Lactobacillus plantarum
(cumulative volume is 5mL to SC9 and β-lg solution, and the concentration of splenocyte is 2 × 106Individual cell/mL, the concentration of Lactobacillus plantarum SC9 is
106The concentration of CFU/mL, β-lg is 1mg/mL), the 4th hole adds the treatment group mice spleen suspended with complete cell culture fluid
(cumulative volume is 5mL, and the concentration of splenocyte is 2 × 10 for cell, Lactobacillus plantarum SC9 and β-lg solution6Individual cell/mL, plant breast
The concentration of bacillus SC9 is 106The concentration of CFU/mL, β-lg is 1mg/mL).
3, after completing step 2, take described 6 porocyte culture plates, add a cover and be placed on 37 DEG C, 5%CO2Quiescent culture in incubator
48 hours.
4, after completing step 3,3000r/min is centrifuged 10min, takes supernatant (spleen cell cultures supernatant).
5, taking the spleen cell cultures supernatant that step 4 obtains, detect the concentration of IL-4, IFN-γ and IL-10 respectively, result is shown in
Table 1.
Splenocyte is secreted the impact (pg/mL, X ± SD) of IL-4, IFN-γ and IL-10 by table 1 Lactobacillus plantarum SC9
| Packet | IL-4 | IFN-γ | IL-10 |
| Blank group | 42.30±1.81 | 629.00±13.23 | 379.19±4.12 |
| Sensitization group | 672.94±10.10* | 327.33±12.58* | 283.95±22.96* |
| Prevention group | 62.29±5.13# | 415.67±20.45 | 350.61±39.33 |
| Treatment group | 59.06±8.87# | 1529.00±26.05*# | 326.81±39.33 |
Note: *, compared with blank group (P < 0.05)；#, compared with sensitization group (P < 0.05).
Compared with blank group, in sensitization group mouse boosting cell culture supernatant, IL-4 secretion level significantly raises, and IFN-γ divides
Bleeding is flat to be significantly reduced, and IL-10 secretion level is also remarkably decreased.Compared with sensitization group, treatment group mouse boosting cell culture supernatant
Middle IFN-γ secretion level dramatically increases, and IL-4 secretion level significantly reduces, and IL-10 secretion level raises.Compared with sensitization group,
In prevention group mouse boosting cell culture supernatant, IFN-γ secretion level increases, and IL-4 secretion level significantly reduces, and IL-10 secretes water
Flat rising.
Four, the impact of Lactobacillus plantarum SC9 IgE total on mice serum level
IgE plays an important role in anaphylaxis, and this anaphylaxis produced by IgE mediation can betide local, also
Whole body can be betided.IgE, IgE is produced at mastocyte and basophil when stimulating body after body first contacts anaphylactogen
Cellular surface combines and makes body is sensitization.
First pluck eyeball before putting to death experimental animal and take blood, the change of IgE level in detection mice serum.Result is shown in Fig. 1 (* table
Show P < 0.05 compared with sensitization group).In sensitization group mice serum, IgE content is significantly higher than blank group (P < 0.05), prevention group and
IgE level in treatment group mice serum is all substantially less than sensitization group (P < 0.05).Result shows, Lactobacillus plantarum SC9 can lead to
Cross reduction body total IgE level (P < 0.05) and alleviate anaphylaxis.
Five, the impact that mouse Colon tectology is changed by Lactobacillus plantarum SC9
The modal symptom of performance of cow milk protein allergy is gastroenteropathy.The absorption of about 50% protein needs 12
Duodenum 12 and whole small intestinal participate in jointly.These proteantigens may span across intestinal epithelial barrier, is operated by cell or by microcreping pleat
Cellular uptake.Food protein can pass through epithelium scattering and permeating, and several proinflammatory cytokines can strengthen Epithelial Permeability, at this
In the case of Xie, food protein can arrive mucosal lymphoid cell induction antibody in a large number and immune complex produces.There are some researches prove
The reaction of Th2 type cell secretion of cytokines can be caused after Naive T cells susceptible individual sensitization.Cell-mediated reaction determines
The release of the specific cells factor and the activation of Th2 type lymphocyte, such as secretion IL-4, IL-10 and IL-5, IL-13, promote
IgE produces and amplifies inflammatory reaction such as chemotactic eosinophilic granulocyte, mastocyte, neutrophilic granulocyte and natural killer cell, causes
Broiler chick and the change of mucosal function.
Put to death after experimental animal, take colon, fix through 10% neutral formalin, make paraffin section, carry out haematoxylin-
After eosin stains, Fig. 2 is shown in pathology section.Naive mice Colonic Struture Changes is clear；Compared with blank group, sensitization group mice
Colon shows the phenomenon of substantially damage, and intestinal villus is the most damaged, and structure is unclear, and enteraden epithelial cell majority necrosis takes off
Fall；Compared with sensitization group, prevention group and treatment group mice intestinal villus epithelial cell have no that obvious necrosis comes off, and intestinal villus arrangement
The most neat.
Six, the impact that mice lungs tectology is changed by Lactobacillus plantarum SC9
Cow milk protein allergy can cause allergic asthma.To the pulmonary of abdominal cavity sensitized mice and grinding of trachea pathological change
In studying carefully, find that red and swollen phenomenon substantially occurs in pulmonary by mouse lung tissue is observed, and go out with near blood vessel or bronchus
Show substantial amounts of lymphocyte, mononuclear cell, eosinophilic granulocyte, bronchus goblet cell, and bronchial lumen is full of mucus.
Put to death after experimental animal, take lungs, fix through 10% neutral formalin, make paraffin section, carry out haematoxylin-
After eosin stains, Fig. 3 is shown in pathology section.Naive mice lung tissue clear in structure；Compared with blank group, sensitization group lungs
Organization table reveals the phenomenon such as blood capillary and venous congestion, hyperemia, alveolar collapse；Compared with sensitization group, prevention group and treatment group
The congestion of the lungs of mice, congested phenomenon are obviously improved.
Claims (10)
1. Lactobacillus plantarum is used for the application preventing and/or treating in the product of allergy in preparation；Described Lactobacillus plantarum is for planting
Thing lactobacillus (Lactobacillus plantarum) SC9, its deposit number is CCTCC NO.M 208150.
Apply the most as claimed in claim 1, it is characterised in that: described product is food, health product or medicine.
Apply the most as claimed in claim 1 or 2, it is characterised in that: described allergy is food anaphylaxis.
4. Lactobacillus plantarum application in preparing product；Described Lactobacillus plantarum is Lactobacillus plantarum (Lactobacillus
Plantarum) SC9, its deposit number is CCTCC NO.M 208150；
The function of described product is at least one in following (a1) to (a24):
(a1) treatment allergy；
(a2) pre-hypo-allergenic；
(a3) treatment food anaphylaxis；
(a4) prevention food anaphylaxis；
(a5) treatment Lac Bovis seu Bubali beta lactoglobulin allergy；
(a6) prevention Lac Bovis seu Bubali beta lactoglobulin allergy；
(a7) treatment allergic asthma；
(a8) prevention allergic asthma；
(a9) treatment irritable bowel syndrome pathological changes；
(a10) prevention irritable bowel syndrome pathological changes；
(a11) treatment irritable bowel syndrome tissue injury；
(a12) prevention irritable bowel syndrome tissue injury；
(a13) treatment Allergic pulmonary pathological changes；
(a14) prevention Allergic pulmonary pathological changes；
(a15) treatment Allergic pulmonary damage；
(a16) prevention Allergic pulmonary damage；
(a17) serum total IgE level is reduced；
(a18) allergy sufferers serum total IgE level is reduced；
(a19) level of splenocyte secretion IL-4 is reduced；
(a20) level of allergy sufferers splenocyte secretion IL-4 is reduced；
(a21) level of splenocyte secretion of gamma-IFN is improved；
(a22) level of allergy sufferers splenocyte secretion of gamma-IFN is improved；
(a23) level of splenocyte secretion IL-10 is improved；
(a24) level of allergy sufferers splenocyte secretion IL-10 is improved.
Apply the most as claimed in claim 4, it is characterised in that: described product is food, health product or medicine.
6. the application as described in claim 4 or 5, it is characterised in that: described allergy is food anaphylaxis.
7., for preventing and/or treat a product for allergy, its active component is Lactobacillus plantarum；Described Lactobacillus plantarum is
Lactobacillus plantarum (Lactobacillus plantarum) SC9, its deposit number is CCTCC NO.M 208150.
8. a product, its active component is Lactobacillus plantarum；Described Lactobacillus plantarum is Lactobacillus plantarum
(Lactobacillus plantarum) SC9, its deposit number is CCTCC NO.M 208150；
The function of described product is at least one in following (a1) to (a24):
(a1) treatment allergy；
(a2) pre-hypo-allergenic；
(a3) treatment food anaphylaxis；
(a4) prevention food anaphylaxis；
(a5) treatment Lac Bovis seu Bubali beta lactoglobulin allergy；
(a6) prevention Lac Bovis seu Bubali beta lactoglobulin allergy；
(a7) treatment allergic asthma；
(a8) prevention allergic asthma；
(a9) treatment irritable bowel syndrome pathological changes；
(a10) prevention irritable bowel syndrome pathological changes；
(a11) treatment irritable bowel syndrome tissue injury；
(a12) prevention irritable bowel syndrome tissue injury；
(a13) treatment Allergic pulmonary pathological changes；
(a14) prevention Allergic pulmonary pathological changes；
(a15) treatment Allergic pulmonary damage；
(a16) prevention Allergic pulmonary damage；
(a17) serum total IgE level is reduced；
(a18) allergy sufferers serum total IgE level is reduced；
(a19) level of splenocyte secretion IL-4 is reduced；
(a20) level of allergy sufferers splenocyte secretion IL-4 is reduced；
(a21) level of splenocyte secretion of gamma-IFN is improved；
(a22) level of allergy sufferers splenocyte secretion of gamma-IFN is improved；
(a23) level of splenocyte secretion IL-10 is improved；
(a24) level of allergy sufferers splenocyte secretion IL-10 is improved.
9. product as claimed in claim 7 or 8, it is characterised in that: described product is food, health product or medicine.
10. the product as described in claim 7 or 8 or 9, it is characterised in that: described allergy is food anaphylaxis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610633406.2A CN106262931A (en) | 2016-08-04 | 2016-08-04 | Lactobacillus plantarum application in preparation antiallergic product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610633406.2A CN106262931A (en) | 2016-08-04 | 2016-08-04 | Lactobacillus plantarum application in preparation antiallergic product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106262931A true CN106262931A (en) | 2017-01-04 |
Family
ID=57664868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610633406.2A Pending CN106262931A (en) | 2016-08-04 | 2016-08-04 | Lactobacillus plantarum application in preparation antiallergic product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106262931A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108504597A (en) * | 2018-03-30 | 2018-09-07 | 南昌大学 | A kind of allergic reaction lactobacillus and its application for alleviating beta lactoglobulin induction |
| CN110771682A (en) * | 2019-11-27 | 2020-02-11 | 江西中医药大学 | Antiallergic yogurt and preparation method thereof |
| CN112280706A (en) * | 2020-10-10 | 2021-01-29 | 内蒙古普泽生物制品有限责任公司 | Lactobacillus plantarum capable of adjusting IgE (immunoglobulin E), improving immune tolerance and resisting allergy and application |
| WO2021071292A3 (en) * | 2019-10-08 | 2021-06-10 | 한국식품연구원 | Composition, using lactobacillus plantarum strain or like, for alleviation of respiratory diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1767839A (en) * | 2003-03-13 | 2006-05-03 | 麒麟麦酒株式会社 | Antiallergic composition |
| CN101018853A (en) * | 2004-09-10 | 2007-08-15 | 麒麟麦酒株式会社 | Method for stabilizing the antiallergic activity of lactic acid bacteria aganst high-temperature treatment, stabilized compositions, and food and drink |
| CN101098957A (en) * | 2005-01-04 | 2008-01-02 | 卡尔皮斯株式会社 | Method of producing lactic acid bacterium having antiallergic effect |
| CN105105145A (en) * | 2015-09-14 | 2015-12-02 | 吉林省农业科学院 | Lactobacillus plantarum and application thereof in preparing functional food for reducing blood glucose and blood fat |
-
2016
- 2016-08-04 CN CN201610633406.2A patent/CN106262931A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1767839A (en) * | 2003-03-13 | 2006-05-03 | 麒麟麦酒株式会社 | Antiallergic composition |
| CN101018853A (en) * | 2004-09-10 | 2007-08-15 | 麒麟麦酒株式会社 | Method for stabilizing the antiallergic activity of lactic acid bacteria aganst high-temperature treatment, stabilized compositions, and food and drink |
| CN101098957A (en) * | 2005-01-04 | 2008-01-02 | 卡尔皮斯株式会社 | Method of producing lactic acid bacterium having antiallergic effect |
| CN105105145A (en) * | 2015-09-14 | 2015-12-02 | 吉林省农业科学院 | Lactobacillus plantarum and application thereof in preparing functional food for reducing blood glucose and blood fat |
Non-Patent Citations (1)
| Title |
|---|
| 王水泉 等: ""植物乳杆菌的生理功能及应用"", 《中国农业科学导报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108504597A (en) * | 2018-03-30 | 2018-09-07 | 南昌大学 | A kind of allergic reaction lactobacillus and its application for alleviating beta lactoglobulin induction |
| CN108504597B (en) * | 2018-03-30 | 2021-03-26 | 南昌大学 | Lactobacillus for relieving beta-lactoglobulin-induced anaphylactic reaction and application thereof |
| WO2021071292A3 (en) * | 2019-10-08 | 2021-06-10 | 한국식품연구원 | Composition, using lactobacillus plantarum strain or like, for alleviation of respiratory diseases |
| CN114615898A (en) * | 2019-10-08 | 2022-06-10 | 韩国食品研究院 | Composition for improving respiratory system diseases using Lactobacillus plantarum strain or the like |
| CN110771682A (en) * | 2019-11-27 | 2020-02-11 | 江西中医药大学 | Antiallergic yogurt and preparation method thereof |
| CN112280706A (en) * | 2020-10-10 | 2021-01-29 | 内蒙古普泽生物制品有限责任公司 | Lactobacillus plantarum capable of adjusting IgE (immunoglobulin E), improving immune tolerance and resisting allergy and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100908254B1 (en) | Antiallergic composition | |
| US20230000932A1 (en) | New use of lactobacillus paracasei subsp. paracasei k56 in alleviation of intestinal inflammation | |
| Kozyrovska et al. | Kombucha microbiome as a probiotic: a view from the perspective of post-genomics and synthetic ecology | |
| CN108570436B (en) | Lactobacillus plantarum ZJUF T17 and application thereof | |
| CN102791849B (en) | Lactic acid bacterium-containing preparation | |
| CN102399718B (en) | Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof | |
| CN106262931A (en) | Lactobacillus plantarum application in preparation antiallergic product | |
| US20100143303A1 (en) | Composition comprising lactic acid bacterium having high anti-allergic activity, and method for production of the lactic acid bacterium | |
| JP2009510053A (en) | Composition for improving intestinal flora and enhancing immune function comprising cinnamon extract as an active ingredient | |
| CN111575204B (en) | Lactobacillus paracasei capable of relieving or treating allergic diseases and application thereof | |
| EP2510932A1 (en) | Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny | |
| Faujdar et al. | Role of probiotics in human health and disease: an update | |
| KR101644594B1 (en) | Lactobacillus casei 1- 2- Composition for Preventing Improving or Treating of 1-mediated Immune Disease or 2-mediated Immune Disease Comprising Extracts from Lactobacillus casei as an Active Ingredients | |
| Xie et al. | Lactobacillus for the treatment and prevention of atopic dermatitis: Clinical and experimental evidence | |
| CN112273657A (en) | Probiotic composition for preventing or improving allergic diseases, preparation method and application | |
| Casaro et al. | Prophylactic Bifidobacterium adolescentis ATTCC 15703 supplementation reduces partially allergic airway disease in Balb/c but not in C57BL/6 mice | |
| CN110892914A (en) | New application of lactobacillus paracasei K56 in improvement of asthma and related allergic symptoms | |
| Chuang et al. | Effects of curcuma longa l., eucommia ulmoides oliv. and gynostemma pentaphyllum (Thunb.) makino on cytokine production in stimulated peripheral blood mononuclear cells in patients with tuberculosis | |
| CN111560335A (en) | Bifidobacterium lactis for relieving asthma and application thereof | |
| EP2332557A1 (en) | Probiotic lactic acid bacteria | |
| JP2007054081A (en) | Antiallergic food including ground lotus and/or lotus extract and lactic bacteria | |
| JP3947778B2 (en) | Anti-allergic agent containing crushed lotus and / or extract and lactic acid bacteria | |
| JP2006257040A (en) | INHIBITOR FOR PRODUCTION OF ALLERGEN-SPECIFIC IgE ANTIBODY AND FOOD AND BEVERAGE USED FOR SUPPRESSING THE PRODUCTION OF THE ALLERGEN-SPECIFIC IgE ANTIBODY | |
| TWI453281B (en) | Anti-allergy lactic acid bacteria and the composition thereof | |
| JP7015674B2 (en) | Regulatory T cell differentiation inducer and differentiation induction method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |